Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed.
FMR1 gene
Fragile X mental retardation protein
Intellectual disability
Treatment
Working memory
Journal
Journal of neurodevelopmental disorders
ISSN: 1866-1955
Titre abrégé: J Neurodev Disord
Pays: England
ID NLM: 101483832
Informations de publication
Date de publication:
15 04 2019
15 04 2019
Historique:
received:
14
11
2018
accepted:
20
03
2019
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
4
8
2020
Statut:
epublish
Résumé
Individuals with fragile X syndrome (FXS) typically demonstrate profound executive function (EF) deficits that interfere with learning, socialization, and emotion regulation. We completed the first large, non-pharmacological controlled trial for FXS, designed to evaluate the efficacy of Cogmed, a computer/tablet-based working memory (WM) training program. The study was a randomized, blinded, parallel two-arm controlled trial in 100 children and adolescents with FXS (63 male, 37 female; 15.28 ± 3.36 yrs.). Participants were randomized equally to adaptive (difficulty level adjusted to performance) or non-adaptive (control) Cogmed training. Participants were assessed at home using objective measures of WM (primary outcome) and EF at baseline, following 20-25 caregiver-supported sessions over 5-6 weeks, and at follow-up 3 months after cessation of training. Parents and teachers provided ratings of WM, attention, and EF. The WM composite and selective domains of EF (distractibility, cognitive flexibility), as well as parent- and teacher-reported attention and EF, significantly improved across the full study sample, with many changes maintained at follow-up. However, comparisons of improvement between adaptive and non-adaptive control conditions did not differ, showing that progressively challenging the WM system by expanding span length did not provide added benefit overall. Further experimental comparisons are needed before Cogmed working memory training can be considered empirically validated for children with FXS, forming the basis of treatment recommendation. However, given that prior studies show no significant changes on these measures in FXS without treatment, that improvements were maintained for 3 months, and that blinded teachers reported improvements in the classroom, the modest benefits seen in both adaptive and non-adaptive groups overall are unlikely to be attributable to placebo or practice effects alone. Future analyses examining inter-individual differences (e.g., baseline capacity, training efficiency, co-morbidity, training environment, characteristics of training aide) may help to link this intervention to outcomes and potential transfer effects. US National Institutes of Health (ClinicalTrials.gov), NCT02747394 .
Sections du résumé
BACKGROUND
Individuals with fragile X syndrome (FXS) typically demonstrate profound executive function (EF) deficits that interfere with learning, socialization, and emotion regulation. We completed the first large, non-pharmacological controlled trial for FXS, designed to evaluate the efficacy of Cogmed, a computer/tablet-based working memory (WM) training program.
METHODS
The study was a randomized, blinded, parallel two-arm controlled trial in 100 children and adolescents with FXS (63 male, 37 female; 15.28 ± 3.36 yrs.). Participants were randomized equally to adaptive (difficulty level adjusted to performance) or non-adaptive (control) Cogmed training. Participants were assessed at home using objective measures of WM (primary outcome) and EF at baseline, following 20-25 caregiver-supported sessions over 5-6 weeks, and at follow-up 3 months after cessation of training. Parents and teachers provided ratings of WM, attention, and EF.
RESULTS
The WM composite and selective domains of EF (distractibility, cognitive flexibility), as well as parent- and teacher-reported attention and EF, significantly improved across the full study sample, with many changes maintained at follow-up. However, comparisons of improvement between adaptive and non-adaptive control conditions did not differ, showing that progressively challenging the WM system by expanding span length did not provide added benefit overall.
CONCLUSIONS
Further experimental comparisons are needed before Cogmed working memory training can be considered empirically validated for children with FXS, forming the basis of treatment recommendation. However, given that prior studies show no significant changes on these measures in FXS without treatment, that improvements were maintained for 3 months, and that blinded teachers reported improvements in the classroom, the modest benefits seen in both adaptive and non-adaptive groups overall are unlikely to be attributable to placebo or practice effects alone. Future analyses examining inter-individual differences (e.g., baseline capacity, training efficiency, co-morbidity, training environment, characteristics of training aide) may help to link this intervention to outcomes and potential transfer effects.
TRIAL REGISTRATION
US National Institutes of Health (ClinicalTrials.gov), NCT02747394 .
Identifiants
pubmed: 30982467
doi: 10.1186/s11689-019-9264-2
pii: 10.1186/s11689-019-9264-2
pmc: PMC6463634
doi:
Banques de données
ClinicalTrials.gov
['NCT02747394']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Subventions
Organisme : NICHD NIH HHS
ID : U54 HD079125
Pays : United States
Références
Am J Med Genet A. 2005 Jan 1;132A(1):25-32
pubmed: 15551333
Neuropsychologia. 2002;40(8):1343-9
pubmed: 11931937
Front Hum Neurosci. 2012 Oct 02;6:271
pubmed: 23060775
J Med Genet. 2008 Aug;45(8):498-9
pubmed: 18413371
Dev Sci. 2009 Jan;12(1):106-13
pubmed: 19120418
Brain Inj. 2007 Jan;21(1):21-9
pubmed: 17364516
Clin Psychol Rev. 2013 Dec;33(8):1237-52
pubmed: 24120258
J Neurodev Disord. 2012 Feb 08;4(1):2
pubmed: 22958782
J Am Acad Child Adolesc Psychiatry. 2005 Feb;44(2):177-86
pubmed: 15689731
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3615-20
pubmed: 14993603
J Intellect Disabil Res. 2011 Jan;55(1):19-29
pubmed: 21121991
Psychol Bull. 2012 Jul;138(4):628-654
pubmed: 22409508
Am J Psychiatry. 2001 Jul;158(7):1040-51
pubmed: 11431225
J Neurodev Disord. 2011 Sep;3(3):193-210
pubmed: 21484200
J Neurodev Disord. 2009 Mar;1(1):33-45
pubmed: 19865612
J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):402-8
pubmed: 11314565
Am J Intellect Dev Disabil. 2013 May;118(3):179-92
pubmed: 23734613
J Clin Exp Neuropsychol. 2002 Sep;24(6):781-91
pubmed: 12424652
Appl Neuropsychol Child. 2014;3(3):163-72
pubmed: 25010082
Child Neuropsychol. 2018 May;24(4):427-450
pubmed: 28277151
Rev Neurol. 2001 Oct;33 Suppl 1:S24-9
pubmed: 12447815
Dev Sci. 2011 May;14(3):591-601
pubmed: 21477197
J Neurodev Disord. 2016 Sep 06;8(1):35
pubmed: 27602170
Value Health. 2014 Nov;17(7):A575
pubmed: 27201927
Dev Psychol. 2013 Feb;49(2):270-91
pubmed: 22612437
J Child Psychol Psychiatry. 2014 Aug;55(8):886-96
pubmed: 24628438
J Appl Res Mem Cogn. 2012 Mar 1;1(1):58-60
pubmed: 22448346
J Pediatr Genet. 2014 Sep;3(3):147-56
pubmed: 27625871
Nat Rev Drug Discov. 2018 Apr;17(4):280-299
pubmed: 29217836
J Child Psychol Psychiatry. 2016 Dec;57(12):1380-1389
pubmed: 27550746
Neuropsychologia. 2000;38(9):1261-70
pubmed: 10865102
PLoS One. 2015 Jul 30;10(7):e0133316
pubmed: 26226597
J Child Psychol Psychiatry. 2014 Mar;55(3):247-55
pubmed: 24117656
Neuropsychologia. 2007 Apr 9;45(8):1889-98
pubmed: 17254617
Nat Neurosci. 2004 Jan;7(1):75-9
pubmed: 14699419